tirzepatide is it a glp 1 Decoding GLP-1 Weight Loss Medications Molecular structure of tirzepatide and

Ramireddy L, Tsen H-Y, Chiang Y-C, Hung C-Y, Wu S-R, Young S-L, Lin J-S, Huang C-H, Chiu S-H, Chen C-C

phase 2 weight-loss data published in 2023 reported mean reductions of roughly 24% at the highest dose over 48 weeks, and phase 3 trials are underway

Oral hyperpigmentation is not uncommon in HIV+ people44

Risks related to anesthesia, aspiration, and retained gastric contents Reports of retained gastric contents and aspiration risk have increased with the widespread use of GLP-1RAs

No side effects after the first few days

The TRIUMPH-4 data are part of an ongoing Phase III program, and regulatory submissions to the FDA and other agencies have not yet been completed